The Pune-based firm has collaborated with the Gamaleya Research Institute of Epidemiology and Microbiology, Moscow for developing Sputnik V at its Hadapsar facility.
Serum Institute of India seeks DCGI s nod to manufacture Sputnik V
Russia s Sputnik V vaccine is currently being manufactured by Dr Reddy s Laboratories in India
New Delhi: The Serum Institute of India (SII) has applied to the Drug Controller General of India (DCGI) seeking permission to manufacture the Sputnik V COVID-19 vaccine for examination, test and analysis at its licensed Hadapsar facility in Pune, official sources said on Thursday.
The Pune-based firm has collaborated with the Gamaleya Research Institute of Epidemiology and Microbiology, Moscow for developing Sputnik V at its Hadapsar facility.
On May 18, the SII had also applied to the Review Committee on Genetic Manipulation (RCGM), Department of Biotechnology seeking clearance for the import of strains or seed lots and cell banks and for carrying out research and development, the sources said.
Technology > Biotech & pharma
14 April 2021
Gennova Biopharmaceuticals Ltd s novel mRNA-based Covid-19 vaccine candidate `HGCO19’ being developed under `Mission Covid Suraksha’, implemented by Biotechnology Industry Research Assistance Council (BIRAC), has moved into clinical trials, says a DBT release.
DBT, which functions under the ministry of science and technology, has also approved additional funding towards clinical studies of India s first of its kind mRNA-based Covid-19 vaccine - HGCO19 - developed by Pune-based biotechnology company Gennova Biopharmaceuticals Ltd.
This funding has been awarded under the Mission Covid Suraksha, being implemented by DBT s dedicated mission implementation unit at Biotechnology Industry Research Assistance Council (BIRAC).
The programme is being implemented after multiple rounds of evaluation of all the applications that were submitted in response to the Request for Expression of Interest (REOI) under Mission COVID Suraksha for th
Share
Vaccine Discovery Programme supported by the Department of Biotechnology, Govt. of India under the Mission COVID Suraksha- The Indian COVID-19 Vaccine Development Mission, implemented by BIRAC, moves into clinical trials
The Department of Biotechnology (DBT), Ministry of Science & Technologyhas announced that it has approved additional funding towards clinical studies of India’s’first of its kind’ mRNA-based COVID-19 vaccine – HGCO19, developed by Pune-based biotechnology company Gennova Biopharmaceuticals Ltd.
This funding has been awarded under the’Mission COVID Suraksha- The Indian COVID-19 Vaccine Development Mission’by DBT’s dedicated Mission Implementation Unit at BiotechnologyIndustry Research Assistance Council (BIRAC) after multiplerounds of evaluation of all the applications that were submitted in response to the ‘Request for Expression of Interest (REOI)’under Mission COVID Surakshafor the’Development of COVID-19 vaccine candidate(s)’.